Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
23.38
-0.36 (-1.52%)
Jul 24, 2026, 4:00 PM EDT - Market closed

Nurix Therapeutics Stock Forecast

Stock Price Forecast

According to 16 analysts polled by S&P Global, Nurix Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $33. The average 1-year stock price forecast is 41.15% higher than the current stock price, while the lowest is $25 (+6.93%) and the highest is $45 (+92.47%).

Price Target: $33 (+41.15%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$25$33$33.5$45
Change+6.93%+41.15%+43.28%+92.47%

Analyst Ratings

The average analyst rating for Nurix Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jun '26Jul '26
Strong Buy12121212109
Buy555555
Hold000011
Sell000000
Strong Sell000000
Total171717171615

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
UBS
UBS
Buy
Reiterates
$23$31
BuyReiterates$23$31+32.59%Jul 22, 2026
Wells Fargo
Wells Fargo
Hold
Maintains
$25
HoldMaintains$25+6.93%Jul 14, 2026
Mizuho Securities
Mizuho Securities
Buy
Maintains
$30$34
BuyMaintains$30$34+45.42%Jul 13, 2026
Oppenheimer
Oppenheimer
Buy
Maintains
$28
BuyMaintains$28+19.76%Jul 10, 2026
RBC Capital
RBC Capital
Buy
Reiterates
$30$33
BuyReiterates$30$33+41.15%Jul 10, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
57.74M
from 83.98M
Decreased by -31.25%
Revenue Next Year
96.40M
from 57.74M
Increased by 66.95%
EPS This Year
-2.72
from -3.05
EPS Next Year
-2.15
from -2.72
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingNov 30, 2021Nov 30, 2022Nov 30, 2023Nov 30, 2024Nov 30, 2025Nov 30, 2026
Revenue
29.75M38.63M76.99M54.55M83.98M57.74M
Revenue Growth
66.95%29.84%99.31%-29.15%53.95%-31.25%
Operating Income
-117.89M-183.87M-155.06M-213.03M-285.67M-323.53M
Net Income
-117.19M-180.36M-143.95M-193.57M-264.46M-303.02M
EPS
-----3.05-2.72
Free Cash Flow
-37.70M-79.42M-41.93M-85.90M-143.99M-222.00M
No. Analysts
-----12
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High93.3M
Avg57.7M
Low33.4M

Revenue Growth

Revenue Growth202620272028
High
11.1%
Avg
-31.2%
Low
-60.3%

EPS Forecast

EPS202620272028
High-2.15
Avg-2.72
Low-3.11

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-